Table 2.
Concurrent immunosuppressant use | ||||
---|---|---|---|---|
No | Yes | |||
Population | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment |
N | 28 | 22 | 9 | 8 |
CD3+ | 387 [262, 570] | 512 [313, 837] | 299 [118, 759] | 397 [202, 783] |
CD3+/CD4+ | 260 [173, 393] | 348 [211, 576] | 207 [79, 542] | 293 [143, 602] |
CD3+/CD8+ | 107 [75, 153] | 134 [84, 213] | 82 [34, 199] | 96 [52, 175] |
CD4:CD8 | 2.43 [1.96, 3.01] | 2.58 [2.03, 3.28] | 2.53 [1.77, 3.62] | 3.03 [2.11, 4.36] |
CD3–/CD16+CD56+ | 7 [4, 11] | 7 [4, 11] | 6 [2, 20] | 7 [2, 21] |
CD3–/CD19+ | 4 [2, 6] | 3 [2, 5] | 7 [2, 24] | 7 [3, 18] |
Values are cells/mL [apart from CD4:CD8].